OR WAIT null SECS
July 01, 2025
Article
The FDA distributed several designations and many trials successfully met their endpoints during an eventful June for hematology.
June 30, 2025
An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22
June 23, 2025
Parent company Novo Nordisk has announced intentions to submit the treatment for approval later in 2025.
Data from the Phase 1/2 BEACON trial indicate the efficacy and safety of this investigative 1-time therapy, particularly in decreasing blood cell sickling.
June 21, 2025
Hereditary hemorrhagic telangiectasia has no approved treatments; this designation, in addition to the European Medicines Agency granting a positive opinion, positions DIAG723 to be the first.
June 20, 2025
Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.
June 14, 2025
An audio recap of the top 5 stories in healthcare news from the week of 06/02-06/08.
Stay updated with the latest healthcare breakthroughs, including FDA approvals and new phase 3 clinical trial data, in this week's essential news roundup.
June 12, 2025
An ongoing phase 1 study aims to prove the safety and tolerability of VAS-101, as well as its effect on blood flow dynamics, red blood cell sickling, and oxygen dissociation.
Novartis has announced the safety and efficacy of iptacopan, a twice-daily oral monotherapy for adult patients who switched from eculizumab or ravulizumab.
